 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Gatiflo, Tequin, Zymar, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a605012 |
| Routes of administration | Eye drops, by mouth (discontinued), IV (discontinued)[1] |
| Drug class | Fluoroquinolone[2] |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Protein binding | 20% |
| Elimination half-life | 7 to 14 hours |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C19H22FN3O4 |
| Molar mass | 375.400 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Gatifloxacin, sold under the brand name Tequin among others, is an antibiotic used to treat bacterial conjunctivitis.[2] It is used as an eye drop.[2]
Common side effect effects include eye pain, abnormal taste, and increased redness of the eyes.[2] Other side effects may include allergic reactions.[2] It is in the fluoroquinolone family and works by inhibits the bacterial enzymes DNA gyrase and topoisomerase IV.[2]
Gatifloxacin was patented in 1986 and approved for medical use in 1999.[3] The by mouth and injectable formulations were withdrawn in the United States in 2006 due to the side effects of high or low blood sugar.[1]
References edit
- ^ a b "Determination That TEQUIN (Gatifloxacin) Was Withdrawn From Sale for Reasons of Safety or Effectiveness". Archived from the original on 10 May 2021. Retrieved 3 December 2021.
- ^ a b c d e f g h "Gatifloxacin (EENT) Monograph for Professionals". Drugs.com. Archived from the original on 25 November 2020. Retrieved 3 December 2021.
- ^ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 501. ISBN 9783527607495. Archived from the original on 2021-10-31. Retrieved 2021-04-01.